rosoxacin and Urethritis

The treatment of gonococcal infections by quinolones is reviewed. Acrosoxacin is effective, but side effects are relatively common. Ciprofloxacin is effective in single dosage against urogenital gonococcal infections, and probably also against rectal and pharyngeal infections. It is effective against infections by penicillinase-producing Neisseria gonorrhoeae. In vitro, ciprofloxacin is active against Chlamydia trachomatis, and preliminary results indicate that this drug may be of value in the treatment of non-gonococcal urethritis and chlamydial infection. No major side effects of ciprofloxacin therapy in patients with these infections have been reported.

Topics: 4-Quinolones; Anti-Infective Agents; Anti-Infective Agents, Urinary; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; Gonorrhea; Humans; Norfloxacin; Quinolines; Quinolones; Urethritis

A total of 112 male patients presenting with acute gonococcal urethritis were admitted to the hospital. The diagnosis was confirmed by smear, culture, oxidase reaction and sugar fermentation tests. The patients were treated with a single 300 mg capsule of rosoxacin. All patients except one showed adequate response to rosoxacin.

Topics: 4-Quinolones; Acute Disease; Adolescent; Adult; Anti-Infective Agents; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Quinolones; Urethritis

In a controlled trial of rosoxacin in patients with non-gonococcal urethritis (NGU), 150 mg of the antibiotic given twice daily for 10 days was compared with 300 mg triple tetracycline (Deteclo) given twice daily for the same period. Only six (19%) of 31 patients treated with rosoxacin were free of urethritis after 10 days; Chlamydia trachomatis was reisolated from 12 (92%) of 13 patients who were chlamydia positive originally, and Ureaplasma urealyticum was reisolated from 12 (80%) of 15 patients who were ureaplasma positive originally. In contrast, 18 (58%) of 31 patients treated with triple tetracycline were cured clinically after 10 days; C trachomatis was not reisolated from any of 10 patients who were chlamydia positive originally, and U urealyticum was reisolated from only three (17%) of 18 patients who were ureaplasma positive originally. These results were consistent with the antimicrobial inactivity of rosoxacin in vitro and they cannot be reconciled with previous reports of successful use of this antibiotic in NGU. Ureaplasmas were isolated more frequently and in larger numbers from chlamydia negative than from chlamydia positive patients, but it is probable that ureaplasmas resistant to tetracycline were not responsible for persistent urethritis.

Topics: 4-Quinolones; Anti-Bacterial Agents; Bacterial Infections; Chlamydia trachomatis; Clinical Trials as Topic; Drug Administration Schedule; Humans; Male; Microbial Sensitivity Tests; Quinolines; Quinolones; Random Allocation; Tetracyclines; Ureaplasma; Urethritis

Between 3 January and 4 March 1983 we treated 200 male patients diagnosed as having uncomplicated gonococcal urethritis with one of two regimens. They were divided into two groups and randomly assigned to treatment with either 2 g spectinomycin administered intramuscularly (group A) or 300 mg rosoxacin by mouth (group B). Of 187 isolates tested for the production of beta-lactamase, 101 (54%) were penicillinase producing Neisseria gonorrhoeae (PPNG) strains. All 81 cases followed in group A (spectinomycin) were cured, compared with 88.5% (77 out of 87) of the patients followed in group B (rosoxacin). We concluded that rosoxacin at a dosage of 300 mg administered orally was fairly effective in the treatment of gonococcal urethritis in men caused by both PPNG and non-PPNG strains.

Topics: 4-Quinolones; Anti-Bacterial Agents; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Penicillinase; Quinolines; Quinolones; Spectinomycin; Urethritis

Topics: 4-Quinolones; Adolescent; Adult; Anti-Infective Agents; Clinical Trials as Topic; Gonorrhea; Humans; Male; Quinolines; Quinolones; Urethritis

In a randomized, double-blind, dose-ranging study, single oral doses of rosoxacin were used to treat 126 patients with uncomplicated genital or anorectal gonorrhea. Neisseria gonorrhoeae was eradicated from 5 (28%) of 18 men treated with 100 mg, compared with 101 (94%) of 108 men and women treated with 200 mg, 300 mg, or 400 mg (P less than 0.001). Susceptibility to rosoxacin was determined for 6 pretreatment gonococcal isolates from these patients and for 194 stored clinical isolates; 296 (98.7%) of these 300 isolates, including 10 strains of penicillinase-producing N. gonorrhaeae, required a minimal inhibitory concentration of less than or equal to 0.062 microgram/ml. Urethral or cervical infection with Chlamydia trachomatis coexisted with gonococcal infection in 14 (22%) of 63 patients and persisted in 7 of 10 patients treated with rosoxacin. Postgonococcal urethritis developed in 11 (34%) of 32 men who were monitored for 12 to 30 days. Sixty-four subjects (51%) developed transient dizziness, drowsiness, altered visual perceptions, or other symptoms suggestive of central nervous system dysfunction after treatment with rosoxacin, but these symptoms were not clearly dose related. Rosoxacin in doses of greater than or equal to 200 mg appears to be effective for single-dose treatment of uncomplicated gonorrhea, but further studies of its possible central nervous system toxicity are indicated.

Topics: 4-Quinolones; Adolescent; Adult; Anti-Bacterial Agents; Chlamydia trachomatis; Female; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Quinolines; Quinolones; Urethritis

Topics: 4-Quinolones; Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Female; Gonorrhea; Humans; Male; Middle Aged; Quinolines; Quinolones; Urethritis

Topics: 4-Quinolones; Adolescent; Adult; Anti-Infective Agents; Drug Evaluation; Female; Gonorrhea; Humans; Male; Penicillin Resistance; Quinolines; Quinolones; Urethritis